VK-2019 for relapsed/refractory EBV-positive DLBCL
Part of Infections clinical trials.
This trial tests a new drug called VK-2019 for people whose EBV-positive diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this drug can shrink tumors and help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of lymphoma called EBV-positive diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments.
- You have tried all standard treatments that could help, and they are no longer working.
- You are at least 18 years old.
- You are able to walk and take care of yourself (ECOG performance status 0 to 2).
- Your blood counts and organ function (kidney, liver) are within acceptable ranges.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (PD-1 inhibitor, tenofovir, chidamide, and lenalidomide) for people with Epstein-Barr virus (EBV) infections that are causing symptoms. It aims to see if this combination can control the virus and improve health.
This early-stage trial tests KSD-101, a new cell therapy, in patients with EBV-related lymphomas (blood cancers) that have come back or stopped responding to previous treatment. The goal is to see if this treatment can help patients who have limited other options.
This study tests a new injection called KSV01 for people with a type of lymphoma (DLBCL) that has returned or not responded to previous treatments. The goal is to see if it can help shrink tumors or stop the disease from getting worse.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
This study tests a new drug called CN201 (also known as MK-1045) for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Hear when a new Diffuse Large B Cell Lymphoma Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.